Plaque Psoriasis: Future Therapeutic Pipeline

Author(s):

Brad Glick, DO, AOCD, George Han, MD, PhD, and Neal Bhatia, MD, look to the future at what is upcoming in the treatment pipeline for plaque psoriasis treatment.

EP: 1.Plaque Psoriasis: Current Expansion of the Therapeutic Landscape

EP: 2.Shifting Treatment Approaches to Plaque Psoriasis

EP: 3.Current Role of Topical Therapy for Plaque Psoriasis Treatment

EP: 4.Spectrum of Disease and Current Treatment Options for Plaque Psoriasis

EP: 5.Plaque Psoriasis: Escalating Treatment

EP: 6.Communication With Patients About Plaque Psoriasis Treatment

EP: 7.IL-23 inhibitors for Plaque Psoriasis Treatment

EP: 8.Impact of Treatment Mode of Delivery on Patient Adherence and Plaque Psoriasis Treatment Selection

EP: 9.Long-Term Persistence of Biologic Treatment Options for Plaque Psoriasis

EP: 10.IL-23 Inhibitors and the Current Treatment Landscape for Plaque Psoriasis

EP: 11.Long Term Efficacy And Safety Data: IL-23 Inhibitors in Patients with Moderate to Severe Plaque Psoriasis

EP: 12.BMI and Background Comorbidities that Impact Plaque Psoriasis Treatment

EP: 13.Plaque Psoriasis: Older Populations and Skin of Color

EP: 14.Looking Ahead at Clinical Trial Metrics for Plaque Psoriasis

Now Viewing

Plaque Psoriasis: Future Therapeutic Pipeline

EP: 1.Plaque Psoriasis: Current Expansion of the Therapeutic Landscape

EP: 2.Shifting Treatment Approaches to Plaque Psoriasis

EP: 3.Current Role of Topical Therapy for Plaque Psoriasis Treatment

EP: 4.Spectrum of Disease and Current Treatment Options for Plaque Psoriasis

EP: 5.Plaque Psoriasis: Escalating Treatment

EP: 6.Communication With Patients About Plaque Psoriasis Treatment

EP: 7.IL-23 inhibitors for Plaque Psoriasis Treatment

EP: 8.Impact of Treatment Mode of Delivery on Patient Adherence and Plaque Psoriasis Treatment Selection

EP: 9.Long-Term Persistence of Biologic Treatment Options for Plaque Psoriasis

EP: 10.IL-23 Inhibitors and the Current Treatment Landscape for Plaque Psoriasis

EP: 11.Long Term Efficacy And Safety Data: IL-23 Inhibitors in Patients with Moderate to Severe Plaque Psoriasis

EP: 12.BMI and Background Comorbidities that Impact Plaque Psoriasis Treatment

EP: 13.Plaque Psoriasis: Older Populations and Skin of Color

EP: 14.Looking Ahead at Clinical Trial Metrics for Plaque Psoriasis

EP: 15.Plaque Psoriasis: Future Therapeutic Pipeline